A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Latest Information Update: 02 May 2023
At a glance
- Drugs Efanesoctocog alfa (Primary)
- Indications Von Willebrand disease
- Focus Pharmacokinetics
- Sponsors Bioverativ
- 27 Apr 2023 Status changed from recruiting to completed.
- 12 Apr 2022 Planned End Date changed from 25 May 2022 to 25 May 2023.
- 12 Apr 2022 Planned primary completion date changed from 7 May 2022 to 7 May 2023.